{"id":"NCT03653364","sponsor":"Hoffmann-La Roche","briefTitle":"Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms","officialTitle":"A Multicenter, Single-Arm, Open-Label Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Otherwise Healthy Pediatric Patients From Birth to < 1 Year With Influenza-Like Symptoms","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-01-23","primaryCompletion":"2023-04-03","completion":"2023-04-03","firstPosted":"2018-08-31","resultsPosted":"2024-05-17","lastUpdate":"2024-05-17"},"enrollment":49,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Influenza"],"interventions":[{"type":"DRUG","name":"Baloxavir Marboxil","otherNames":[]}],"arms":[{"label":"Baloxavir Marboxil","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the safety, pharmacokinetics and efficacy of baloxavir marboxil in healthy pediatric participants from birth to \\<1 year with influenza like symptoms","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"From Day 1 up to Day 29","effectByArm":[{"arm":"Baloxavir Marboxil","deltaMin":23,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":13},"locations":{"siteCount":27,"countries":["United States","Bulgaria","Costa Rica","Finland","Israel","Poland","Russia","South Africa","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":48},"commonTop":["Diarrhoea","Vomiting"]}}